Free Trial
NASDAQ:SESN

Sesen Bio (SESN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.63
$12.99
52-Week Range
N/A
Volume
93,330 shs
Average Volume
1.07 million shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SESN stock logo

About Sesen Bio Stock (NASDAQ:SESN)

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

SESN Stock News Headlines

Trey Mewes
Sesen Bio (NASDAQ: SESN)
Sesen Bio Receives NASDAQ Delisting Notice
See More Headlines
Receive SESN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
5/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SESN
Employees
35
Year Founded
N/A

Profitability

Net Income
$-19,880,000.00
Pretax Margin
-59.40%

Debt

Sales & Book Value

Annual Sales
$40 million
Book Value
$0.78 per share

Miscellaneous

Free Float
196,980,000
Market Cap
$2.56 billion
Optionable
Optionable
Beta
0.83
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

SESN Stock Analysis - Frequently Asked Questions

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) issued its quarterly earnings data on Sunday, November, 7th. The company reported $7.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.40) by $8.60.

When did Sesen Bio's stock split?

Sesen Bio shares reverse split on the morning of Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

This page (NASDAQ:SESN) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners